Real breakthroughs don’t happen overnight. They take years of persistence, discovery, and vision.
Opticyte’s VitalO₂ Monitor traces its roots back more than 30 years, to PhD research on cellular oxygenation by our CEO and Co-Founder, Lori Arakaki, PhD.
Since then, Lori and our team have spent decades advancing the science of optical spectroscopy, building from foundational discoveries to a device that today has received two FDA Breakthrough Device Designations:
One for noninvasive cellular oxygenation monitoring
One for equitable, accurate pulse oximetry across all skin tones
Few companies achieve one Breakthrough Device recognition. Opticyte has two for the same platform technology.
This is not merely theoretical innovation; we believe this represents significant scientific advancement that has the potential to influence clinical practice.
